Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Neurogene Inc.
13G/A
NGNE · 64135M105
|
4.5% |
8/14/2026
Event 6/30/2026
|
|||
| Trails Edge Capital Partners, LP | 4.5% | ||||
| Trails Edge Biotechnology Master Fund, LP | 4.5% | ||||
| Ortav Yehudai | 4.5% | ||||
|
OnKure Therapeutics, Inc.
13G/A
68227Q105
|
3.6% |
8/14/2026
Event 6/30/2026
|
|||
| Trails Edge Capital Partners, LP | 3.6% | ||||
| Trails Edge Biotechnology Master Fund, LP | 3.6% | ||||
| Ortav Yehudai | 3.6% | ||||
|
Faeth Therapeutics, Inc.
13G/A
FTH · 81728A207
|
2.0% |
8/14/2026
Event 6/30/2026
|
|||
| Trails Edge Capital Partners, LP | 2.0% | ||||
| Trails Edge Biotechnology Master Fund, LP | 2.0% | ||||
| Ortav Yehudai | 2.0% | ||||
|
Camp4 Therapeutics Corp
13G
CAMP · 13463J101
|
6.0% |
8/10/2026
Event 8/3/2026
|
|||
| Trails Edge Capital Partners, LP | 6.0% | ||||
| Trails Edge Biotechnology Master Fund, LP | 6.0% | ||||
| Ortav Yehudai | 6.0% | ||||
|
Research Alliance Corporation IV
13G
RACD · G75228109
|
5.5% |
7/21/2026
Event 7/14/2026
|
|||
| Trails Edge Capital Partners, LP | 5.5% | ||||
| Trails Edge Biotechnology Master Fund, LP | 5.5% | ||||
| Ortav Yehudai | 5.5% | ||||
|
Research Alliance Corporation III
13G
RACC · G75226103
|
5.5% |
5/29/2026
Event 5/21/2026
|
|||
| Trails Edge Capital Partners, LP | 5.5% | ||||
| Trails Edge Biotechnology Master Fund, LP | 5.5% | ||||
| Ortav Yehudai | 5.5% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
IKT · 45719W205
|
6.1% |
5/15/2026
Event 3/31/2026
|
|||
| Trails Edge Capital Partners, LP | 6.1% | ||||
| Trails Edge Biotechnology Master Fund, LP | 6.1% | ||||
| Ortav Yehudai | 6.1% | ||||
|
ImageneBio, Inc.
13G
IMA · 45175G207
|
9.9% |
4/21/2026
Event 4/14/2026
|
|||
| Trails Edge Capital Partners, LP | 9.9% | ||||
| Trails Edge Biotechnology Master Fund, LP | 9.9% | ||||
| Ortav Yehudai | 9.9% | ||||
|
OnKure Therapeutics, Inc.
13G
OKUR · 68277Q105
|
6.0% |
4/7/2026
Event 3/31/2026
|
|||
| Trails Edge Capital Partners, LP | 6.0% | ||||
| Trails Edge Biotechnology Master Fund, LP | 6.0% | ||||
| Ortav Yehudai | 6.0% | ||||
|
Milestone Pharmaceuticals Inc.
13G/A
MIST · 59935V107
|
4.3% |
3/26/2026
Event 3/20/2026
|
|||
| Trails Edge Capital Partners, LP | 4.3% | ||||
| Trails Edge Biotechnology Master Fund, LP | 4.3% | ||||
| Ortav Yehudai | 4.3% | ||||
|
Immunic, Inc.
13G
IMUX · 4525EP101
|
8.7% |
2/24/2026
Event 2/17/2026
|
|||
| Trails Edge Capital Partners, LP | 8.7% | ||||
| Trails Edge Biotechnology Master Fund, LP | 8.7% | ||||
| Ortav Yehudai | 8.7% | ||||
|
X4 Pharmaceuticals, Inc.
13G/A
XFOR · 98420X202
|
5.8% |
2/17/2026
Event 12/31/2025
|
|||
| Trails Edge Capital Partners, LP | 5.8% | ||||
| Trails Edge Biotechnology Master Fund, LP | 5.8% | ||||
| Ortav Yehudai | 5.8% | ||||
|
ProMIS Neurosciences Inc.
13G
PMN · 74346M505
|
9.9% |
2/10/2026
Event 2/3/2026
|
|||
| Trails Edge Capital Partners, LP | 9.9% | ||||
| Trails Edge Biotechnology Master Fund, LP | 9.9% | ||||
| Ortav Yehudai | 9.9% | ||||
|
LB Pharmaceuticals Inc
13G
LBRX · 50180M108
|
5.0% |
12/31/2025
Event 12/24/2025
|
|||
| Trails Edge Capital Partners, LP | 5.0% | ||||
| Trails Edge Biotechnology Master Fund, LP | 5.0% | ||||
| Ortav Yehudai | 5.0% | ||||
|
vTv Therapeutics Inc.
13G
VTVT · 918385204
|
9.9% |
9/8/2025
Event 8/29/2025
|
|||
| Trails Edge Capital Partners, LP | 9.9% | ||||
| Trails Edge Biotechnology Master Fund, LP | 9.9% | ||||
| Ortav Yehudai | 9.9% | ||||